KBC Securities on Friday moved Philips (AS:PHG) up its recommendation to buy from accumulate after the company reported a robust first quarter and kept its guidance unchanged. The broker highlighted the reaffirmation of the outlook as a positive signal, even while noting an expectation for a softer second quarter.
In its assessment, KBC Securities said Philips seems relatively well equipped to manage inflationary cost pressures and challenges linked to China - factors the broker sees as creating a competitive advantage versus some peers. The upgrade follows a period in which other major healthcare equipment groups, specifically GE Healthcare (NASDAQ:GEHC) and Siemens Healthineers (ETR:SHLG), have trimmed their guidance.
The broker also described Philips as attractively valued, commenting that the current share price does not yet reflect the company’s recent performance. Despite the upgrade, shares were trading down about 1% on the day, in line with broader European market movements.
This assessment from KBC Securities balances near-term caution - a softer Q2 - against the confirmation of the company’s existing outlook and apparent resilience to certain cost and regional challenges. The note implies that while momentum may ease in the coming quarter, the underlying fundamentals demonstrated in the first quarter provide a basis for a more positive rating.
Market reaction and positioning
- Shares of Philips were down roughly 1% on the trading day, moving in step with wider European indices.
- KBC Securities upgraded the stock to buy, citing the company’s ability to navigate cost inflation and difficulties in China relative to peers.
- GE Healthcare and Siemens Healthineers have both lowered guidance, a contrast that the broker used to underscore Philips’ comparatively stronger stance.
Analytical takeaway
The broker’s upgrade rests on the combination of solid first-quarter results, the firm’s decision to stand by its guidance, and the view that valuation is attractive given recent performance. KBC Securities does, however, signal an expectation of a softer second quarter, which suggests a watchful stance in the near term despite the improved recommendation.